Panelists debate how to select between axicabtageneciloleucel and lisocabtagenemaraleucel for patients with rapidly progressive second-line DLBCL. Key arguments examine differences in efficacy signals, vein-to-vein time, and toxicity profiles and how these factors influence urgency of treatment. Faculty explore how real-world experience, institutional infrastructure, and patient-specific risk factors and lifestyle shape optimal CAR T product selection.
